• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

SAR446523 Granted Orphan Drug Designation for Patients With Relapsed, Refractory Multiple Myeloma

by MM360 Staff | Aug 1, 2025 | Myeloma News

Source: Pharmacy Times articles Sanofi’s SAR446523 receives orphan drug designation for relapsed refractory multiple myeloma, enhancing treatment options and patient outcomes. Read More

FDA Grants Orphan Drug Status to SAR446523 for Relapsed Myeloma

by MM360 Staff | Aug 1, 2025 | Uncategorized

Source: CureToday articles SAR446523, an investigational antibody targeting GPRC5D, received FDA orphan drug status and is in phase 1 trials for relapsed/refractory multiple myeloma. Read More

Outcomes following different upfront stem cell transplantation strategies for multiple myeloma: a statistical perspective on behalf of the Chronic Malignancies Working Party of the EBMT

by MM360 Staff | Jul 31, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement

by MM360 Staff | Jul 31, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Expert: Linvoseltamab’s Simplified Dosing Expands Access, Enhances Tolerability in Multiple Myeloma

by MM360 Staff | Jul 31, 2025 | Myeloma News

Source: Pharmacy Times articles Sundar Jagannath, MD, MBBS, discusses how linvoseltamab’s streamlined step-up dosing and REMS program support broader use in community settings and improved tolerability for older patients. Read More
« Older Entries
Next Entries »

Recent Content

  • Prognostic and clinicopathological value of prognostic nutritional index in patients with multiple myeloma: a meta-analysis
  • Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses
  • Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003)
  • (no title)
  • The risk of second primary malignancies in patients receiving T-cell directed therapies for multiple myeloma: a systematic review
  • (no title)
  • Impact of residual clonal plasma cells in S-phase at the time of autologous stem cell transplantation on clinical outcomes
  • (no title)
  • Efficacy and toxicity of treatment of smoldering multiple myeloma: a systematic review and meta-analysis
  • (no title)
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT